These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11267627)

  • 1. Bromocriptine-induced dissociation of hyperglycemia and prolactin response to restraint.
    Ribeiro-de-Oliveira A; Guerra RM; Fóscolo RB; Marubayashi U; Reis AM; Coimbra CC
    Pharmacol Biochem Behav; 2001 Feb; 68(2):229-33. PubMed ID: 11267627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of chronic bromocriptine (CB-154) treatment on the plasma glucose and insulin secretion response to neurocytoglucopenia in rats.
    Ribeiro-de-Oliveira A; Guerra RM; Fóscolo RB; Marubayashi U; Reis AM; Coimbra CC
    J Endocrinol; 1999 Aug; 162(2):237-42. PubMed ID: 10425461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood glucose and prolactin in hyperprolactinemic rats exposed to restraint and surgical stress.
    Reis FM; Ribeiro-de-Oliveira A; Guerra RM; Reis AM; Coimbra CC
    Life Sci; 1996; 58(2):155-61. PubMed ID: 8606624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic treatment with bromocriptine modifies metabolic adjustments in response to restraint stress in rats.
    Balthazar CH; Ribeiro Oliveira A; Marubayashi U; dos Reis AM; Coimbra CC
    Auton Autacoid Pharmacol; 2007 Apr; 27(2):123-9. PubMed ID: 17391282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women.
    Kamath V; Jones CN; Yip JC; Varasteh BB; Cincotta AH; Reaven GM; Chen YD
    Diabetes Care; 1997 Nov; 20(11):1697-701. PubMed ID: 9353611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor.
    Framnes-DeBoer SN; Bakke E; Yalamanchili S; Peterson H; Sandoval DA; Seeley RJ; Arble DM
    Am J Physiol Endocrinol Metab; 2020 Jan; 318(1):E62-E71. PubMed ID: 31794265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute metabolic effects of thiopental anesthesia on fed and fasted rats chronically treated with bromocriptine.
    de Oliveira AR; Botion LM; Guerra RM; Fóscolo RB; Machado LJ; Marubayashi U; dos Reis AM; Coimbra CC
    J Pharmacol Sci; 2003 Jun; 92(2):149-52. PubMed ID: 12832843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of bromocriptine on serum prolactin levels, pituitary weight and immunoreactive prolactin cells in estradiol-treated ovariectomized rats: an experimental model of estrogen-dependent hyperprolactinemia.
    Ribeiro MF; Spritzer PM; Barbosa-Coutinho LM; Oliveira MC; Pavanato MA; Silva IS; Reis FM
    Braz J Med Biol Res; 1997 Jan; 30(1):113-7. PubMed ID: 9222412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contrasting effects of bromocriptine on learning of a partially baited radial arm maze task in the presence and absence of restraint stress.
    Srikumar BN; Raju TR; Shankaranarayana Rao BS
    Psychopharmacology (Berl); 2007 Aug; 193(3):363-74. PubMed ID: 17468850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.
    Carey RM; Thorner MO; Ortt EM
    J Clin Invest; 1980 Jul; 66(1):10-8. PubMed ID: 7400305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of bromocriptine on corticosterone secretion in male rats.
    Kan SF; Kau MM; Low-Tone Ho L; Wang PS
    Eur J Pharmacol; 2003 May; 468(2):141-9. PubMed ID: 12742521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity.
    Maccario M; Grottoli S; Procopio M; Oleandri SE; Barberis A; Ciccarelli E; Camanni F; Ghigo E
    J Endocrinol Invest; 1996 Apr; 19(4):219-23. PubMed ID: 8862501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
    Krysiak R; Okopien B
    Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bromocriptine on responses to stress in spontaneously hypertensive rats.
    Sowers JR
    Hypertension; 1981; 3(5):544-50. PubMed ID: 7028608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hypersecretion of growth hormone and prolactin on plasma levels of glucagon and insulin in GH3-cell-tumor-bearing rats, and the influence of bromocriptine treatment.
    Knudtzon J; Johansen PW; Haug E; Gautvik K
    Life Sci; 1986 Aug; 39(7):617-21. PubMed ID: 3526070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat.
    Uvnäs-Moberg K; Ahlenius S; Alster P; Hillegaart V
    Neuroendocrinology; 1996 Mar; 63(3):269-74. PubMed ID: 8677015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restraint stress decreases afternoon plasma prolactin levels in female rats. Influence of neural antagonists and agonists on restraint-induced changes in plasma prolactin and corticosterone.
    Gala RR; Haisenleder DJ
    Neuroendocrinology; 1986; 43(2):115-23. PubMed ID: 3724981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of serotonin depletion by p-chlorophenylalanine on serum prolactin levels in estrogen-treated ovariectomized rats: insights concerning the serotoninergic, dopaminergic and opioid systems.
    Mallmann ES; Ribeiro MF; Spritzer PM
    Horm Metab Res; 2001 Jun; 33(6):337-42. PubMed ID: 11456281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attempts to pharmacologically modulate prolactin levels and type 1 autoimmune diabetes in the non-obese diabetic (NOD) mouse.
    Durant S; Alves V; Coulaud J; El Hasnaoui A; Dardenne M; Homo-Delarche F
    J Autoimmun; 1995 Dec; 8(6):875-85. PubMed ID: 8824712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased responsiveness to the hyperglycemic, hyperglucagonemic and hyperinsulinemic effects of circulating norepinephrine in ob/ob mice.
    Liang Y; Cincotta AH
    Int J Obes Relat Metab Disord; 2001 May; 25(5):698-704. PubMed ID: 11360153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.